Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon Workers' Health Study (AWHS)
Resumen: Context: Ferritin concentration is associated with metabolic syndrome, but the possibility of a nonlinear association has never been explored.
Objective: This study aimed to examine the relationship between serum ferritin levels and the metabolic syndrome in Spanish adult males.
Design: This was a cross-sectional analysis of baseline data from the Aragon Workers' Health Study.
Setting: Healthy workers from a factory were studied during their annual checkup.
Participants: Spanish male adults (n = 3386) between the ages of 19 and 65 years participated. We excluded participants with ferritin > 500 µg/L, ferritin < 12 µg/L, or C-reactive protein > 10 mg/L.
Main Outcome Measure: Metabolic syndrome was defined according to the 2009 consensus definition from the Joint Interim Statement of several international societies.
Results: Metabolic syndrome prevalence was 27.1%. We found a positive association between elevated iron stores, measured as serum ferritin concentration, and metabolic syndrome and its criteria. Participants within the highest serum ferritin quintile had a higher risk than those in the lowest quintile for central obesity (odds ratio [OR], 1.88; 95% confidence interval [CI], 1.46–2.42), hypertriglyceridemia (OR, 2.15; 95% CI, 1.69–2.74), and metabolic syndrome (OR, 1.92; 95% CI, 1.48–2.49). The association was nonlinear and occurred at serum ferritin concentrations > 100 µg/L (~ 33th percentile). Ferritin was also associated with insulin resistance, measured by homeostatic model assessment–insulin resistance (HOMA-IR) (P trend < .001).
Conclusions: Our findings suggest that serum ferritin is significantly associated with metabolic syndrome and its criteria (especially central obesity and hypertriglyceridemia), suggesting that ferritin could be an early marker of metabolic damage in the development of metabolic syndrome.

Idioma: Inglés
DOI: 10.1210/jc.2014-4409
Año: 2015
Publicado en: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 100, 5 (2015), 2081-2089
ISSN: 0021-972X

Factor impacto JCR: 5.531 (2015)
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 16 / 131 = 0.122 (2015) - Q1 - T1
Factor impacto SCIMAGO:

Financiación: info:eu-repo/grantAgreement/ES/FIS/PI10-00021
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS/CP08-00112
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-01434
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-00009
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI12-01703
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)


Rights Reserved All rights reserved by journal editor


Exportado de SIDERAL (2020-03-31-10:29:16)

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2020-03-31, last modified 2020-03-31


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)